AZ reveals compelling PhIII data for ovarian cancer treatment

pharmafile | October 26, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AZ, AstraZeneca, lynparza 

AstraZeneca has revealed new results from a Phase III trial investigating the efficacy of its Lynparza drug as a monotherapy for the treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.

The results showed that the drug achieved a statistically significant improvement of progression-free survival (PFS) in patients compared to placebo. Median PFS also substantially exceeded what the drug recorded in its Phase II trial studying patients with platinum-sensitive relapsed ovarian cancer. Safety findings remained consistent with earlier data.

The results follow the FDA’s decision to award Lynparza Fast Track Designation earlier this year.

“We are pleased with the robust improvement in progression-free survival demonstrated by Lynparza in the SOLO-2 trial,” commented Sean Bohen, executive VP of Global Medicines Development and CMO at AstraZeneca. “We will work with regulatory authorities to make Lynparza tablets available as quickly as possible to patients with ovarian cancer. We remain committed to investigating the full potential of Lynparza, both as monotherapy and in combinations, and to identifying all patients who may benefit from this important medicine.”

Matt Fellows

Related Content


AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD

AstraZeneca has announced that Ultomiris (ravulizumab) has been approved in Japan as a long-acting C5 …


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso …

Latest content